In studies with breast cancer cell lines in vitro and in vivo, disulfiram not only diminished mammosphere formation (Yip et al., 2011; Kim et al., 2017) and reduced CD44+CD24- and CD49f+CD24+ subpopulations, but also managed to reverse paclitaxel and cisplatin resistance of triple-negative breast cancer (TNBC) (Liu et al., 2013). This evidence concerns the gene CD24 and triple-negative breast carcinoma.